Business Context and Reporting Period
Company: Jazz Pharmaceuticals Plc
Filing Type: Form 8-K (Current Report)
Date of Report: July 28, 2015
Event: Item 8.01 - Other Events regarding patent litigation.
Key Financial Metrics
This filing is a current report regarding legal proceedings and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the decision by the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office to institute inter partes review (IPR) proceedings. This action concerns five patents related to the distribution system for the Company's product Xyrem (sodium oxybate) oral solution. The petitions for review were filed in January 2015 by Amneal Pharmaceuticals LLC and Par Pharmaceutical, Inc.
Outlook, Risks, and Management Commentary
- PTAB Decision: The PTAB instituted trial on certain prior art grounds asserted by the petitioners but rejected other potential grounds for unpatentability.
- Timeline: The Company expects final decisions on the validity of the five patents in approximately 12 months. These decisions will be appealable to the U.S. Court of Appeals for the Federal Circuit.
- Pending Action: The PTAB has not yet notified the Company regarding a sixth patent related to the Xyrem distribution system covered by the same petitions. The Company intends to disclose the decision on this sixth patent in a subsequent Form 10-Q.
- Risk: The outcome of these reviews poses a risk to the validity of the patents protecting the Xyrem distribution system.
Investor Verification Checklist
- Verify the specific claims within the five patents subject to the instituted IPR proceedings.
- Monitor the status of the sixth patent pending PTAB notification.
- Review the Company's future 10-Q filings for the disclosure of the decision on the sixth patent.
- Assess the potential impact of patent invalidation on the exclusivity period for Xyrem.